A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purposes of this study are to:
- Test the safety of DN-101 in patients with advanced malignancies
- Understand how fast the body absorbs, processes, and eliminates DN-101
- Determine the highest dose of DN-101 that is well tolerated by cancer patients
- Learn how fast the body absorbs, processes, and eliminates DN-101 compared to the
approved product